NutrifyGenie AI, a leading AI-driven platform, was integral in designing scientifically differentiated formulations for a multinational client
ICMR will continue to track trends in HMPV circulation throughout the year
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The transaction is expected to result in approximately $175 million to support further development of IMG-007
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
Merck has also decided to end the favezelimab clinical development program
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Subscribe To Our Newsletter & Stay Updated
